Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.57-0.21 (-0.96%)
At close: 4:00PM EDT
21.57 0.00 (0.00%)
After hours: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close21.78
Open21.85
Bid21.00 x 1300
Ask27.00 x 3100
Day's Range21.17 - 21.85
52 Week Range17.51 - 38.49
Volume59,959
Avg. Volume157,587
Market Cap1.083B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis

    Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a non-steroidal treatment intended for chronic use, would be the first and only topical PDE4 inhibitor for psoriasis, if approved.Roflumilast cream demonstrated statistically significant superiority over vehicle on the primary endpoint of IGA Success and statistically significant improvements in multiple se

  • GlobeNewswire

    New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at European Academy of Dermatology and Venereology Congress

    Topical roflumilast provided significant improvements in severity and burden of itch in Phase 3 plaque psoriasis studies, as well as Phase 2 studies in seborrheic dermatitis and scalp and body psoriasis.Quality of life improvements were achieved starting as early as week twoPivotal studies support potential use of roflumilast cream as effective and well-tolerated non-steroidal topical therapy for plaque psoriasis WESTLAKE VILLAGE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutic

  • GlobeNewswire

    Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

    WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced a new patent issued by the United States Patent and Trademark Office covering its invention for improving delivery and extending half-life of both the cream and fo

Advertisement
Advertisement